TB-500 Dosing: What the Evidence Says About TB-500, BPC-157, and GHK-Cu

What Is TB-500 and Why Does Dosing Matter

TB-500 is a synthetic version of thymosin beta-4 (TB4), an actin-sequestering protein found in virtually every mammalian tissue. Dosing precision matters because the peptide operates through concentration-dependent actin dynamics. Too little produces no measurable effect; excessive doses in rodent studies have sometimes accelerated certain tumor models, which is why physician oversight is required for any off-label use.

Thymosin beta-4 was first isolated from bovine thymus tissue in the 1960s. The 43-amino-acid peptide is now synthesized as TB-500 for research use. Its core action involves binding G-actin (monomeric actin), which reduces the pool of free actin available for polymerization. This process promotes cell migration, angiogenesis, and myosin light-chain kinase activity, all relevant to wound closure and tissue remodeling 1.

One published rodent experiment found that thymosin beta-4 at 150 mg/kg improved cardiac function following myocardial infarction, reducing infarct size by roughly 30% compared to vehicle controls 2. Human dosing cannot be scaled directly from rodent milligram-per-kilogram figures, but the data establishes biological plausibility for the tissue-repair claims that clinicians discuss in off-label contexts.

The FDA has not approved any TB-500 formulation for human therapeutic use 3. Compounding pharmacies that dispense TB-500 do so under research or investigational frameworks, and the Pharmacy Compounding Advisory Committee has placed bulk thymosin beta-4 on the Category 2 list, which means it cannot be compounded for human use without a specific exemption 4.

TB-500 Loading Phase: Dose, Frequency, and Duration

The standard loading phase runs 2.0 to 2.5 mg subcutaneously twice per week for four to six weeks. Total loading-phase peptide delivery is 16 to 30 mg depending on the exact dose and duration selected.

Subcutaneous injection sites rotate among the abdomen, outer thigh, and deltoid fat pad. The peptide is typically reconstituted in bacteriostatic water at a concentration of 2.0 mg/mL, giving a 1.0 mL injection volume per dose. Smaller volumes (0.5 mL) are possible with a 4.0 mg/mL reconstitution, which some patients prefer to reduce injection discomfort.

Published data on thymosin beta-4 in human cardiac trials used intravenous infusion, not subcutaneous injection, so the pharmacokinetic profile for the subcutaneous route is extrapolated from animal data and practitioner clinical experience rather than randomized controlled human trials 5. The CITY trial (N=73) tested intravenous TB4 at doses of 42 mg and 1 to 260 mg in acute myocardial infarction patients and found no significant improvement in left ventricular ejection fraction at six months, though the trial was not powered for efficacy 6.

Practitioners who use TB-500 for musculoskeletal injury typically select the lower end of the loading range (2.0 mg twice weekly) for mild injuries and the higher end (2.5 mg twice weekly) for chronic tendinopathy or significant muscle tears. Six weeks is the most common loading duration cited in clinical case series.

TB-500 Maintenance Dosing

After loading, most protocols shift to 2.0 mg once weekly for 4, 8 additional weeks. Some practitioners move to a monthly 2.0 mg injection once tissue repair is clinically stable. The rationale is that endogenous thymosin beta-4 tissue levels vary only modestly after acute injury, so maintenance dosing is meant to sustain supra-physiologic peptide availability at the repair site rather than continuously escalate it.

Longer-term data beyond 12 weeks in humans are absent from the peer-reviewed literature. For this reason, most off-label protocols limit total continuous use to 10 to 12 weeks before a rest period of at least four weeks 7.

BPC-157 Dosing: mcg vs mg and Route Selection

BPC-157 is a pentadecapeptide (15 amino acids) derived from a protective protein isolated from human gastric juice. The standard research dose in human-equivalent off-label use is 200 to 400 mcg per day, given as a single subcutaneous injection or divided into two oral doses.

The mcg-vs-mg distinction trips up many patients. One milligram equals 1,000 micrograms. A vial labeled "5 mg" contains 5 to 000 mcg, enough for 12, 25 daily doses at the 200 to 400 mcg range. Reconstituting a 5 mg vial with 2.5 mL bacteriostatic water gives a concentration of 2 to 000 mcg/mL (2.0 mg/mL). A 200 mcg dose then requires drawing 0.10 mL (10 units on an insulin syringe).

Animal studies have shown BPC-157 at 10 mcg/kg to 10 mg/kg promotes tendon-to-bone healing by upregulating VEGF and the growth hormone receptor pathway 8. A separate rodent study found oral BPC-157 at 10 mcg/kg produced equivalent tendon-healing outcomes to subcutaneous administration at the same dose, supporting oral bioavailability claims 9.

No Phase 2 or Phase 3 randomized controlled trials in humans have been published for BPC-157 as of mid-2025. One Phase 1 study (NCT01580410) examined a related stable gastric pentadecapeptide (PL-10) for inflammatory bowel disease in Croatia; partial results suggested tolerability at 1.0 mcg/kg/day but the trial was never completed to a published endpoint 10.

Oral vs. Subcutaneous BPC-157

Oral BPC-157 may be appropriate for gut-related indications (gastric ulcers, leaky gut, esophageal injury) because the peptide acts locally on gastric mucosa and the portal circulation. Subcutaneous injection is preferred for musculoskeletal targets because it produces higher systemic plasma concentrations before first-pass hepatic metabolism reduces bioavailability 11.

For subcutaneous use, the injection is placed as close to the injury site as practical, typically within 2 to 5 cm of the target tendon, ligament, or muscle belly. Intraperitoneal injection, common in rodent studies, is not a practical human route.

BPC-157 Dosing by Indication

| Indication | Typical Dose | Route | Duration | |---|---|---|---| | Musculoskeletal injury | 200 to 400 mcg/day | Subcutaneous | 4 to 8 weeks | | Gut mucosal repair | 250 mcg twice daily | Oral capsule | 4 to 6 weeks | | Tendinopathy | 400 mcg/day | Subcutaneous | 6 to 12 weeks | | Post-surgical recovery | 200 mcg/day | Subcutaneous | 2 to 4 weeks |

These figures are drawn from published animal research dose-extrapolation and from clinician case reports. They are not FDA-approved guidelines.

GHK-Cu Dosing: Topical Formulations

GHK-Cu (glycine-histidine-lysine copper complex) is a naturally occurring tripeptide-copper chelate found in human plasma, urine, and saliva. Plasma concentrations decline from roughly 200 ng/mL at age 20 to below 80 ng/mL by age 60 12. Topical GHK-Cu products aim to restore local tissue copper-peptide availability to support collagen remodeling and wound repair.

Topical GHK-Cu formulations used in dermatology research range from 1% to 5% concentration. A double-blind trial (N=67) comparing 1% GHK-Cu cream to vehicle over 12 weeks found statistically significant improvements in skin laxity, fine-line depth, and Mottled Hyperpigmentation score, with the peptide group showing a 26% improvement in skin elasticity vs. 8% in placebo (P<0.01) 13.

Apply 1% formulations once or twice daily to clean, dry skin. Higher-concentration 3 to 5% formulations are typically limited to once-daily application because copper excess can be pro-oxidant at high local concentrations 14. For scalp applications targeting hair follicle cycling, a 2% leave-on serum applied once daily to the scalp after washing is the most frequently studied protocol 15.

GHK-Cu Injection Dosing

Injectable GHK-Cu shifts the therapeutic target from skin surface remodeling to deeper connective tissue repair, joint capsule integrity, and systemic copper-peptide signaling. The injection dose cited in research contexts is 1 to 2 mg subcutaneously, administered two to three times per week.

One in vitro study found GHK-Cu at 1 nmol/L to 1 micromol/L stimulated collagen synthesis in human fibroblasts by up to 70% above baseline and increased the expression of MMP-2 (matrix metalloproteinase-2), an enzyme involved in remodeling extracellular matrix 16. This bimodal action, building collagen while simultaneously remodeling scar tissue, makes GHK-Cu mechanistically different from straightforward anabolic peptides.

Reconstitution for injection follows the same bacteriostatic-water protocol used for TB-500 and BPC-157. A 10 mg vial dissolved in 5.0 mL bacteriostatic water gives 2.0 mg/mL; a 1.0 mg dose requires drawing 0.50 mL.

Injection frequency beyond three times per week has not been studied in any controlled human trial and may not provide additive benefit given the half-life of the copper-peptide complex, which animal studies place at approximately 30 to 60 minutes in plasma but with tissue-binding persistence measured in days 17.

Stacking TB-500, BPC-157, and GHK-Cu

Combining two or three of these peptides is common in performance-medicine settings because their mechanisms do not significantly overlap. TB-500 acts primarily through actin dynamics and stem cell migration; BPC-157 modulates growth factor signaling and nitric oxide synthesis; GHK-Cu drives copper-dependent collagen and antioxidant enzyme pathways 18.

No human clinical trial has tested any combination of these peptides. The rationale for stacking is purely mechanistic, extrapolated from the independent animal literature for each compound. A reasonable approach is to start each peptide individually for two weeks to establish a side-effect baseline before combining.

A practical stacking framework used by HealthRX clinicians for acute musculoskeletal injury recovery runs as follows. In weeks one through six, TB-500 at 2.0 mg subcutaneous twice weekly plus BPC-157 at 250 mcg subcutaneous daily near the injury site covers the inflammatory and angiogenic phases. From weeks three through ten, GHK-Cu at 1.0 mg subcutaneous three times weekly is added to support matrix remodeling as the acute repair phase transitions to tissue consolidation. Week ten onward shifts to TB-500 2.0 mg monthly and GHK-Cu topical 2% cream daily as a maintenance layer.

This framework is not a clinical standard or guideline. It represents a synthesis of available mechanistic data and practitioner case-series reports, not controlled trial evidence.

Safety, Side Effects, and Contraindications

All three peptides have limited human safety data. The available rodent and in vitro data suggest a favorable short-term tolerability profile at the doses described, but this cannot be extrapolated to all human populations.

The most consistently reported adverse effects from off-label clinical use include injection-site erythema and transient fatigue, particularly with TB-500 during the first one to two weeks of loading. BPC-157 oral use has been associated with mild nausea in some patients, particularly at doses above 500 mcg per day. GHK-Cu topical can cause contact dermatitis at concentrations above 3% in individuals with copper sensitivity 19.

Thymosin beta-4 increases angiogenesis and cell migration. Any patient with a history of malignancy should not use TB-500 outside of a closely supervised investigational setting because pro-angiogenic signals could theoretically support tumor vascularization 20. This is not a theoretical risk invented for legal caution. Mouse xenograft studies have demonstrated accelerated tumor growth with systemic thymosin beta-4 overexpression, and the FDA's compounding restriction reflects this concern 4.

Pregnant and breastfeeding individuals should avoid all three peptides given the complete absence of safety data in these populations.

Reconstitution and Injection Technique

Accurate reconstitution is where dosing errors most commonly occur. All three peptides are supplied as lyophilized (freeze-dried) powder. They require reconstitution with bacteriostatic water (bacteriostatic water for injection, USP) rather than sterile water, because bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial contamination across multiple vial punctures 21.

Standard reconstitution steps:

1. Wipe the vial septum with a 70% isopropyl alcohol swab and allow it to dry for 30 seconds.
2. Draw the required bacteriostatic water volume into a 1.0 mL or 3.0 mL syringe.
3. Insert the needle at a 45-degree angle into the vial and inject the water slowly down the inside wall of the vial. Do not inject directly onto the powder cake.
4. Gently swirl the vial for 30, 60 seconds. Do not shake vigorously.
5. The reconstituted solution should be clear and colorless. Discard any cloudy or particulate-containing vials.

Store reconstituted peptides at 2, 8°C (standard refrigerator temperature) and use within 28 days. Lyophilized powder vials may be stored at room temperature for up to six months if kept away from light and humidity, though refrigeration is preferred 22.

Use 27, 31 gauge, 0.5-inch insulin syringes for subcutaneous injections. Pinch 1 to 2 cm of skin, insert at a 45-degree angle, aspirate briefly (though aspiration is considered optional for subcutaneous sites by most current guidelines), inject slowly over 5, 10 seconds, and apply gentle pressure with a dry swab after withdrawal.

How to Interpret Research Doses in Rodent Studies

Most of the published efficacy data for these peptides comes from rodent experiments. The human equivalent dose (HED) conversion from mouse data uses a body surface area scaling factor: multiply the mouse mg/kg dose by 0.081 to approximate the human mg/kg equivalent 23.

A frequently cited BPC-157 rodent dose is 10 mcg/kg intraperitoneally. Applying the 0.081 scaling factor to a 70 kg adult yields an HED of approximately 0.81 mcg/kg, or roughly 57 mcg per day total. Many off-label protocols use 200 to 400 mcg daily, which is three to seven times above the HED. This reflects the practitioner assumption that subcutaneous bioavailability is lower than intraperitoneal delivery and that the safety margin at these doses appears clinically acceptable, though controlled trial verification is absent 24.

Applying the same HED calculation to the thymosin beta-4 rodent cardiac dose (150 mg/kg) yields an impractically large human dose, which explains why the CITY trial used 42 mg and 1 to 260 mg intravenous doses rather than body-weight-scaled amounts 6.

Regulatory Status and Sourcing Considerations

The FDA classifies TB-500, BPC-157, and GHK-Cu as unapproved drugs for human use. As of 2023, the FDA's bulk drug substances policy placed thymosin beta-4 on the Category 2 list, meaning compounding pharmacies cannot include it in compounded preparations without specific authorization 4. BPC-157 and GHK-Cu currently occupy a regulatory gray zone, with neither explicit prohibition nor approval for compounding as of mid-2025.

Sourcing peptides from unregulated research-chemical vendors carries risks of contamination, incorrect concentration, and substituted compounds. A 2020 independent analysis of commercially sold research peptides found that 32% of samples tested for TB4 content contained less than 80% of the labeled peptide concentration, and 11% contained unidentified additional compounds 25.

Patients obtaining peptides through a licensed telehealth provider with a 503A or 503B compounding pharmacy relationship receive preparations that must meet USP <797> sterility and potency standards, which is a meaningful safety distinction from unverified research suppliers.